TRENDS

Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers

April 3, 2018
By Reiji Anasako Eisai is offloading its generic subsidiary Elmed Eisai to Japan’s largest generic maker, Nichi-Iko Pharmaceutical. Among innovative pharma companies, it is the first divestment of a generic business since one by Mitsubishi Tanabe Pharma a year ago,…

To read the full story

Related Article

TRENDS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…